• Citer

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials

par Borges, Alvaro Humberto;Huedo-Medina, Tania Bibiana;Hughes, Michael J.M.B.;Huppler Hullsiek, Katherine;Khabo, Paul;Komati, Stephanus;Kumar, Princy Suresh;Lockman, Shahin;MacArthur, Rodger R.D.;Maggiolo, Franco;Matteelli, Alberto;Lundh, Andreas;Miró, José María;Oka, Shinichi;Petoumenos, Kathy;Puls, Rebekah R.L.;Riddler, Sharon S.A.;Sax, Paul Edward Dward P.E.;Sierra-Madero, Juan;Torti, Carlo;Lundgren, Jens D;Tendal, Britta;Bartlett, John J.A.;Clumeck, Nathan ;Costagliola, Dominique;Daar, Eric E.S.;Echeverría, Patrícia;Gisslén, Magnus
Référence Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 63, 2, page (268-280)
Publication Publié, 2016-07

Article révisé par les pairs

• Détails
• Contenu

Résumé :

BACKGROUND: Previous studies suggest that nonnucleoside reverse-transcriptase inhibitors (NNRTIs) cause faster virologic suppression, while ritonavir-boosted protease inhibitors (PI/r) recover more CD4 cells. However, individual trials have not been powered to compare clinical outcomes.